Liquidia slumps as US FDA holds back final approval for blood pressure drug

Liquidia

19/08/2024 12:32

(Updates)
    ** Shares of Liquidia Corp  LQDA.O  fall 38% to $8.75
premarket 
    ** U.S. FDA grants tentative approval to co's inhaled blood
pressure drug Yutrepia, but stops short of a traditional
approval
    ** Tentative approval indicates Yutrepia has met all
regulatory standards for quality, safety and efficacy required
for approval but must await the expiration of regulatory
exclusivity of a competing product before final approval can be
granted - LQDA
    ** Co says final approval of Yutrepia may occur after
expiration of regulatory exclusivity of United Therapeutics'
 UTHR.O  Tyvaso on May 23, 2025 
    ** LQDA says it will challenge FDA's decision to grant
regulatory exclusivity to UTHR's Tyvaso 
    ** Shares of UTHR up 6.7% at $342.40 premarket
    ** Up to last close, LQDA up 17.3% and UTHR up 46% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))